proactive monitoring of cancer as an alternative to surgery
From 2016 -2019, the first PRISAR consortium implemented the first Dutch RISE project of H2020 to investigate the use of imaging technologies and hybrid fluorescence/radionuclide probes for the surgical intervention of cancer. Thi...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
PRISAR
Preclinical Intra Operative Image Guided Surgery and Post Op...
2M€
Cerrado
SURVIVE
Integrating cancer detection and SURgery Via molecular Imagi...
2M€
Cerrado
MOBODICT
Noninvasive Monitoring of Blood Flow and Oxygen Dynamics as...
169K€
Cerrado
CerISMA
Cerenkov Imaging for Surgical Margin Assessment
2M€
Cerrado
PROSENSE
Cancer Diagnosis Parallel Sensing of Prostate Cancer Biomar...
4M€
Cerrado
PRE2020-092859
BIOSENSORES PARA DESENTRAÑAR EL LEGADO Y EL FUTURO DE LA EPI...
99K€
Cerrado
Información proyecto PRISAR2
Duración del proyecto: 63 meses
Fecha Inicio: 2019-12-02
Fecha Fin: 2025-03-31
Líder del proyecto
PERCUROS BV
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
2M€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
From 2016 -2019, the first PRISAR consortium implemented the first Dutch RISE project of H2020 to investigate the use of imaging technologies and hybrid fluorescence/radionuclide probes for the surgical intervention of cancer. This PRISAR project provided a career-enabling human resource plethora of inter-disciplinary and inter-sectoral secondments, which resulted in the development, of not only a hybrid probe for image-guided surgery, but also a variety of tools and instruments. We now propose a new project, PRISAR2, to implement the next logical phase of this work, which is to clinically translate new and innovative monitoring technologies from industry. This will provide better patient selection and increase the surveillance window to allow for better treatment options over time and avoid surgery. This will involve developing new ‘watch and wait’ strategies to study the behaviour of the cancer so that any risks can be minimized. This would lead to a better clinical outcome and quality of life (QOL) for the patient and maximize the benefits of an active monitoring policy for both the patient and the healthcare system. When a patient is discovered to have cancer, one of the primary goals is to have the tumour removed by surgery. Here, however, we aim to (a) develop new monitoring technologies from industry so that the surveillance window can be increased to allow for better treatment options over time and to avoid surgery, (b) develop new ‘watch and wait’ strategies in order to study the behaviour of the cancer so that any risks to the patient can be minimised leading to a better clinical outcome and (c) train a new generation of preclinical and clinical scientists to be able to implement this new concept as standard of care and to maximise the benefits of an active monitoring policy.